The Law Offices of Frank R. Cruz announces an investigation of BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On June 29, 2023, BioXcel disclosed that it is conducting an investigation into protocol adherence and data integrity at the principal investigator’s trial site in connection with the Company’s TRANQUILITY II clinical trial. BioXcel warned that developments relating to its TRANQUILITY II Phase 3 trial may also “impact the timing of the Company’s development plans for, and prospects for regulatory approval” of its Alzheimer’s drug, BXCL501.

On this news, BioXcel’s stock price fell as much as 66% during intraday trading on June 29, 2023, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased BioXcel securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230629901929/en/